Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valeo Pharma Inc T.VPH

Alternate Symbol(s):  T.VPH.DB | VPHIF

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


TSX:VPH - Post by User

Comment by eric40on Aug 22, 2020 11:05am
170 Views
Post# 31441539

RE:$6M Bought Deal Financing

RE:$6M Bought Deal FinancingFrom what I know, the syndicate of underwriters came to Valeo with the bought deal.
They want to take a position but couldn't buy on the market because of limited float that creates huge swing in the SP when they start buying.

This is good sign of confidence and interest in the cie.

With the 5 products coming to market in the next 4-5 months, the revenu will increase by 3X to 5X within 1 year, and the market cap will follow the same path.

Big pharma in the making with excellent business model with no risky R&D, just product that generates growing revenu that are immune from recession. I love it

Even more, with covid 19, government spent so much money and created huge deficit, they will have to cut expenses. This tells me that all the provinces will follow British Colombia and 3 other provinces and order by law to buy generics when available.

With Redeska coming in september, and being the only generic heparin (bio similar) of the 200 millions Canadian heparin market, there is a good chance that Redeska will grab a significant part of the market.

And Redeska is one of many allready on the market or coming to the market for Valeo.

The big players start to discover Valeo. It is just a matter of time for Valeo SP to increase at new higher level IMHO.



<< Previous
Bullboard Posts
Next >>